Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, Citigroup Analyst Says

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by Citigroup from $37.00 to $45.00 in a report issued on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus boosted their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. UBS Group assumed coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target on the stock. Barclays upped their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, August 15th. StockNews.com raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 15th. Finally, The Goldman Sachs Group increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.64.

Syndax Pharmaceuticals Stock Down 2.2 %

NASDAQ:SNDX opened at $15.60 on Tuesday. Syndax Pharmaceuticals has a 52 week low of $15.00 and a 52 week high of $25.34. The company has a market cap of $1.33 billion, a PE ratio of -4.30 and a beta of 0.92. The business’s 50 day moving average is $18.71 and its two-hundred day moving average is $20.08.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter last year, the business earned ($0.73) earnings per share. As a group, sell-side analysts expect that Syndax Pharmaceuticals will post -3.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new position in Syndax Pharmaceuticals during the second quarter worth about $27,000. Values First Advisors Inc. acquired a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $30,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $33,000. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals during the third quarter valued at approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).